COVID-19 and its economic impacts have only strengthened the rationale for the development of a strong biosimilar market as health systems seek to reduce costs and make life-changing treatments available to patients across broader regions of the globe.
At Cromos Pharma, we have extensive experience and expertise in managing early and late phase clinical trials for biosimilars by facilitating efficient and effective patient recruitment and retention across our operations in Eastern Europe and CIS Region. We are also experienced in design and management of the initial Phase I studies in healthy volunteers and can offer Cromos-coordinated support of our preferred biosimilar partners, uniquely experienced Phase I units in EU, US and Australia.
|Our COO, Stephanie Finnegan would be delighted to fill you in on the specific benefits of working with Cromos Pharma and discuss opportunities for collaboration on your next biosimilar program. Email us at email@example.com to set up a time for a virtual meeting.|
Remember to follow and post updates relating to the event by using #GRxBiosims
Cromos Pharma is looking forward to taking part in the upcoming DIA Europe conference (15 – 19 March 2021). A highly collaborative event, it’s a great chance to meet with future partners and hear from innovators across the entire life sciences spectrum.
Cromos Pharma is delighted to be participating in MAGI’s Clinical Research vConference (2-5 & 9-12 November). Our CEO Vlad Bogin, MD, FACP will be giving a presentation on the timely topic of Crisis Management (2 November, 2:30 PM-3:30 PM).